Non-Small-Cell Lung Cancer (Locally Advanced)

Title	Published	Price
Freedonia Focus on Cancer Therapies By: Freedonia Focus This report discusses US demand for cancer therapies for the years 2003 and 2008, with forecasts for 2013. Topics covered include market size, product and market segmentation, types of cancer, diagnosis and screening, technology \| more...	11/30/2009	$500.00
Prostate Cancer Drug Discoveries: What the Future Holds By: Espicom Healthcare Intelligence Prostate cancer is the second leading cause of cancer in the US and the third most common cancer worldwide. More than two million men in the US suffer with prostate cancer. Find out more about \| more... Search inside this report	11/5/2009	$2,460.00
Protein Kinase Therapeutics in Oncology - Where to Commercialize? By: BioSeeker Group AB This report comprises defined and up to date development strategies for 409 protein kinase drugs (990 projects) within the portfolio of 160 investigators, from Ceased to Marketed. The report extensively analyses 133 identified targets of \| more...	10/29/2009	$3,500.00
CDK Inhibitors Patent Landscape 2009 By: France Innovation Scientifique et Transfer IP Overview presents a patent landscape analysis of the CDK Inhibitor field. Alterations in CDK activity have been associated in the development of viral infections, neurodegenerative dis orders such as Alzheimer’s disease and proliferative \| more... Search inside this report	10/29/2009	$1,645.00
Pipeline Insight: Colorectal Cancer - Growing trend towards personalized medicine By: Datamonitor Introduction CRC incidence will be over 490,000 cases by 2018 in the seven major markets. This large patient base will translate into a high commercial potential for the development of novel, more effective therapies. Currently, there \| more...	10/21/2009	$11,400.00
Stakeholder Insight: Acute Leukemias - Reaching the limits of cytotoxic chemotherapy By: Datamonitor Introduction The drug therapy of acute myeloid leukemia (AML) and adult acute lymphoblastic leukemia (ALL) is largely based on chemotherapy regimens that have changed little in the past few decades. Patient outcomes for both diseases remain \| more...	10/8/2009	$15,200.00
Top 20 Cancer Therapy Brands Forecast By: Datamonitor Introduction The cancer therapies market offers a high level of commercial reward to a handful of companies including Roche, Sanofi-Aventis, AstraZeneca, Novartis and Eli Lilly. Cancer therapy sales totaled over $38 billion in the seven major \| more...	10/2/2009	$15,200.00
Oxygen Therapy By: Global Industry Analysts The global outlook series on Oxygen Therapy provides statistical anecdotes, market briefs, and concise summaries of research findings. The report offers an aerial view of the global oxygen therapy industry, identifies major short to medium \| more...	10/1/2009	$950.00
Forecast Insight: Top 20 Cancer Therapy Brands Targeted therapies will drive market growth in the wake of the cytotoxic and antihormonal patent cliff By: Datamonitor Introduction The cancer therapies market offers a high level of commercial reward to a handful of companies including Roche, Sanofi-Aventis, AstraZeneca, Novartis and Eli Lilly. Cancer therapy sales totaled over $38 billion in the seven \| more...	9/22/2009	$15,200.00
Strategic Analysis of the Bladder Cancer Therapeutics By: Intellent In this report, Intellent focuses on the unmet medical need of the global bladder cancer market. Our new primary research driven report focuses on the currently available therapeutics to deal with this disease. Our unique \| more... Search inside this report	9/17/2009	$1,500.00

Phone: 800.298.5699 (US) or +1.240.747.3093 (Int'l)
Hours: 7:00 a.m. to 7:00 p.m. EST Monday through Friday
Email: customerservice@marketresearch.com
Copyright © 1999-2009, All Rights Reserved, MarketResearch.com
11/23/2009 - 2